Microvasculature-brain interaction in diabetes: an ultrahigh field MRI study - SMART-MICRO

niversitair Medisch Centrum Utrecht0 个研究点目标入组 84 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•- Age 50 years or older
•- Understanding of the Dutch language
•- For the diabetes subgroups: participation in UCC-SMART and diabetes mellitus,
•defined as a self-reported history of diabetes, use of oral glucose-lowering
•medication or insulin, or a fasting serum glucose concentration of >=7 mmol/L at
•study inclusion.
•o Type 1 diabetes: diabetes in individuals who immediately needed insulin at
•onset and absence of oral glucose lowering medication.
•o Type 2 diabetes: diabetes in individuals with a self-reported history of type
•2 diabetes, with a referral diagnosis of type 2 diabetes, or use or oral
•glucose-lowering medication
•- For controls, we will include age- and sex-matched controls without diabetes
•who have not been included in UCC-SMART.

•- Diabetes other than type 1 or type 2, e.g., maturity onset diabetes of youth,
•gestational diabetes or diabetes due to pancreatic disease
•- Prediabetes
•- Any general contra-indication for brain MRI, i.e., metallic objects in or
•around the body (e.g., cardiac implantable electronic device such as pacemakers
•and implantable cardioverter defibrillators), claustrophobia or pregnancy
•- Other major neurological or psychiatric conditions affecting the brain and
•interfering with the study design, e.g., multiple sclerosis, epilepsy,
•Parkinson*s disease, prior stroke or vascular dementia
•- Other factors that may limit the interpretation of the study results, i.e.,
•uncontrolled hypertension (defined as systolic or diastolic blood pressure
•>160/110 mmHg with or without use of antihypertensive medication), current
•smoking or BMI >40 kg/m2

发起方

niversitair Medisch Centrum Utrecht